000			02780nam a22002537a 4500
001			20241025104043.0
003			OCoLC
005			20241025104400.0
008			241025b |||||||| |||| 00| 0 eng d
020			_a978-3-030-70772-9
020			_a978-3-030-70773-6 (eBook)
040			_cddc
041			_aEnglish
082			_a616.994 LIM
100			_qGeorgios S. Limouris
245			_aLiver Intra-arterial PRRT with 111In-Octreotide _b The Tumoricidal Efficacy of 111In Auger Electron Emission.
260			_aNuclear Medicine Medical School National and Kapodistrian University of Athens Athens Greece | _bSpringer Nature Switzerland AG | _c 2021
300			_a265 Pages
300			_aIncludes References
520			_aThis book describes in detail a clinical project that reveals the tumoricidal efficacy of Auger and internal conversion electrons, emitted from n.c.a. 111In and implemented in oncology as a treating armamentarium for peptide receptor radionuclide therapy (PRRT), targeting small size (ø ≤ 20 mm) tumors and micro-metastases. The keen interest in n.c.a. 111In began when it was observed that its Auger electron emission could be highly radiotoxic, due to its high LET when it decayed in the vicinity of cellular DNA. The somatostatin analog octreotide, labeled with [111In-diethylenetriaminepentaacetic acid (DTPA0-D-Phe1)] is an established diagnostic agent for the imaging of somatostatin receptor-positive neuro- (or non-neuro) endocrine tumors. It relies on receptor-mediated binding, internalization and installation in the lysosomes in the proximity of the nucleus; administered in large doses, loco-regionally, via the feeding artery of solid tumors, can be highly radiotoxic if they over-express somatostatin receptors, mainly of the sst2 histotype. The book compares the results between i.v. and i.a. implementation in more than 80 patients after over 800 i.a. infusions in neuroendocrine tumors, meningiomas, paragangliomas and colorectal carcinomas in a single Institute (Aretaieion University Hospital) and encourages the i.a. way, leading to “tumor melting”, while minimizing the toxicity to healthy peritumoral liver tissue and critical organs (kidneys and bone marrow). The volume is an invaluable tool for nuclear medicine physicians, interventional radiologists and oncologists dealing with radiopeptide therapies.
600			_xInterventional radiology, Medical / Allied Health Services / Imaging Technologies, Medical / Clinical Medicine, Medical / Oncology / General, Medical / Radiology, Radiotherapy & Nuclear Medicine, Medical / Surgery / General, Nuclear medicine, Oncology, Surgery, Liver -- Cancer -- Radiotherapy.
856			_u https://doi.org/10.1007/978-3-030-70773-6
942			_2ddc _cEB _n0
999			_c29330 _d29330